(Q34186762)

31 July 2017

1 reference

title

The RTS,S vaccine candidate for malaria (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

Christian F Ockenhouse

series ordinal

3

object named as

Christian F Ockenhouse

1 reference

31 July 2017

Jason A Regules

1

1 reference

31 July 2017

James F Cummings

series ordinal

2

1 reference

31 July 2017

publication date

1 May 2011

1 reference

Expert Review of Vaccines

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

589-599

1 reference

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

31 July 2017

cites work

1 reference

Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite

21 January 2018

1 reference

Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

21 January 2018

1 reference

Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite Plasmodium falciparum

21 January 2018

1 reference

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

21 January 2018

1 reference

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

Mechanism of action of clinically approved adjuvants

21 January 2018

1 reference

Advances in saponin-based adjuvants

21 January 2018

1 reference

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

21 January 2018

1 reference

Mechanism of action of licensed vaccine adjuvants

21 January 2018

1 reference

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

21 January 2018

1 reference

TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector

21 January 2018

1 reference

TLR4 agonists as immunomodulatory agents.

21 January 2018

1 reference

Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome

21 January 2018

1 reference

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

Emulsion-based adjuvants for influenza vaccines.

21 January 2018

1 reference

Adjuvants for malaria vaccines

21 January 2018

1 reference

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

21 January 2018

1 reference

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults

21 January 2018

1 reference

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

21 January 2018

1 reference

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

21 January 2018

1 reference

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques

21 January 2018

1 reference

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

21 January 2018

1 reference

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

21 January 2018

1 reference

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

21 January 2018

1 reference

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

21 January 2018

1 reference

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children

21 January 2018

1 reference

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

21 January 2018

1 reference

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon

21 January 2018

1 reference

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

21 January 2018

1 reference

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

21 January 2018

1 reference

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

21 January 2018

1 reference

Evaluation of the safety and immunogenicity of the RTS,S/AS01 E malaria candidate vaccine when integrated in the expanded program of immunization

21 January 2018

1 reference

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

21 January 2018

1 reference

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

21 January 2018

1 reference

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein

21 January 2018

1 reference

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

21 January 2018

1 reference

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

21 January 2018

1 reference

Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys

21 January 2018

1 reference

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.57

1 reference

31 July 2017

1 reference